Last Price
6.42
Today's Change
-0.08 (1.23%)
Day's Change
6.22 - 6.56
Trading Volume
1,328,441
Exchange: Australian Securities Exchange Australian Securities Exchange
Currency: AUD AUD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Dr. Colin David Biggin Ph.D. Dr. Colin David Biggin Ph.D.
Full Time Employees: 50 50
IPO Date: 2021-08-25 2021-08-25
ISIN: AU0000165375 AU0000165375
Beta: 1.58 1.58
Last Dividend: 0.00 0.00
Dcf Diff: 8.35 8.35
Dcf: -1.85 -1.85
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.
National Innovation Centre,
Sydney, NSW 2015, AU
61 2 9209 4037